読み込み中
NASDAQHealthcareBiotechnology
最新データ
$7.47
−$0.03 · -0.40%
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
前日終値
$7.47
−$0.03 · -0.40%
日中の時刻はETです。市場データは遅延する場合があります。
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
日中レンジ
現在 $7.47
52週レンジ
現在 $7.47
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
40
割高
センチメント
44
まちまち
リスク
58
やや高いリスク
モメンタム
41
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
日中レンジ
現在 $7.47
52週レンジ
現在 $7.47
| 指標（USD） | 2025年度 |
|---|---|
| 売上原価 | 2417.6万 USD |
| 粗利益 | −2417.6万 USD |
| 研究開発 | 2.5億 USD |
| 販売・一般管理 | 8862.7万 USD |
| 営業費用 | 3.15億 USD |
| 受取利息 | 1556.6万 USD |
| 支払利息 | 83.7万 USD |
| 減価償却費と償却費 | 2417.6万 USD |
| 営業利益 | −3.39億 USD |
| 純利益 | −3.24億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
下落余地（33.07%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI690.48万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM617.66万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF252.19万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO151.19万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO130.73万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA114.77万0.01%218.24億 USD0.03%$32.79+0.40%
iShares Micro-Cap ETFIWC75.15万0.06%13.17億 USD0.60%$183+0.11%
ALPS Medical Breakthroughs ETFSBIO51.01万0.27%1.91億 USD0.50%$55.04+2.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
